• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Lifeward Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition

    5/15/25 8:16:49 AM ET
    $LFWD
    Industrial Specialties
    Health Care
    Get the next $LFWD alert in real time by email
    false000160796200-0000000Floor 6Yokneam IlitIL+508.251.11544.959.0123Ordinary Shares, par value NIS 0.25NASDAQ00016079622025-05-152025-05-15


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM 8-K

    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): May 15, 2025
     
    Lifeward Ltd.

    (Exact Name of Registrant as Specified in its Charter)
      
    Israel
     
    001-36612
     
    Not Applicable
    (State or Other Jurisdiction of Incorporation)
     
    (Commission File Number)
     
    (IRS Employer Identification No.)

    200 Donald Lynch Blvd. Marlborough, MA
     
    01752
    (Address of principal executive offices)
     
    (Zip Code)
     
    Registrant’s telephone number, including area code: +508.251.1154
      
    Not applicable
    (Former name or former address, if changed since last report)

    Securities registered pursuant to Section 12(b) of the Act:

    Securities registered pursuant to
    Section 12(b) of the Act
     
    Trading Symbol
     
    Name of each exchange on which registered
    Ordinary Shares, par value NIS 1.75
     
    LFWD
     
    Nasdaq Capital Market

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
      
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     


    Item 2.02  Results of Operations and Financial Condition.
     
    On May 15, 2025, Lifeward Ltd. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2025. A copy of the press release is being furnished herewith as Exhibit 99.1. As set forth in the press release, the Company will host a conference call to discuss its financial results for the first quarter ended March 31, 2025, on May 15, 2025 at 8:30 a.m. E.D.T. The archived webcast will be available at https://edge.media-server.com/mmc/p/5e35v6wk. and/or through the Company’s website at www.golifeward.com under the “Investors” section for 30 days after the completion of the call.
     
    The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “1934 Act”), nor shall it be deemed “incorporated by reference” into any filing under the Securities Act of 1933, as amended, or the 1934 Act, except as may be expressly set forth by specific reference in such filing.
     
    (d) Exhibits
     
    99.1
    Press release, dated May 15, 2025, of Lifeward Ltd., announcing financial results for the first quarter ended March 31, 2025.*
     
    104
    Cover Page Interactive Data File (embedded within the Inline XBRL document).
       
    *
    Furnished herewith
     



    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
    Lifeward Ltd.
     
     
     
     
     
    Dated: May 15, 2025
    By:
    /s/ Mike Lawless
     
     
    Name:
    Mike Lawless
     
     
    Title:
    Chief Financial Officer
     


    Get the next $LFWD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LFWD

    DatePrice TargetRatingAnalyst
    2/10/2025$10.00Buy
    Laidlaw
    More analyst ratings

    $LFWD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lifeward Ltd. Reports First Quarter 2025 Financial Results

      U.S. pipeline of ReWalk opportunities continues to build with over 120 qualified leads in process Closure of AlterG sites and resulting consolidation of resources and reduced expenditures yields improved operating expense trend Second consecutive quarter of AlterG revenue growth over 15% reflecting continued sales momentum MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced its financial results for the three months ended March 31, 2025. Recent Highlights and A

      5/15/25 8:00:33 AM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Lifeward Completes Research Program with Israeli Human-Robot Interaction Consortium to Integrate Artificial Intelligence and Exoskeletons

      MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, announced the Company has completed its research program as part of the Israel Innovation Authority's MAGNET incentive program, the Human Robot Interaction Consortium (the "HRI Consortium"). This three-year program provides research and collaboration grants to private businesses and leading academic centers, with the goal of "developing advanced technologies aimed at providing robots with social capabilities, enabling them to carr

      5/8/25 8:30:00 AM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Lifeward to Report First Quarter 2025 Financial Results on May 15, 2025

      MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a  global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its first quarter 2025 financial results before the markets open on Thursday, May 15, 2025. Larry Jasinski, Chief Executive Officer, and Mike Lawless, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EDT to discuss the financial results. To access the call, analysts and investors may utilize the following: Toll free (U.S.)1-833-316-0561International (

      5/7/25 4:30:25 PM ET
      $LFWD
      Industrial Specialties
      Health Care

    $LFWD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Laidlaw initiated coverage on Lifeward with a new price target

      Laidlaw initiated coverage of Lifeward with a rating of Buy and set a new price target of $10.00

      2/10/25 7:00:44 AM ET
      $LFWD
      Industrial Specialties
      Health Care

    $LFWD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Lind Global Fund Ii Lp sold $1,655,009 worth of Ordinary Shares (573,110 units at $2.89) (SEC Form 4)

      4 - Lifeward Ltd. (0001607962) (Issuer)

      1/8/25 5:20:52 PM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Director Richner Randel sold $7,214 worth of Ordinary Shares (4,285 units at $1.68) (SEC Form 4)

      4 - Lifeward Ltd. (0001607962) (Issuer)

      12/17/24 4:08:29 PM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Director Turk Joseph E Jr bought $10,140 worth of Ordinary Shares (6,000 units at $1.69), increasing direct ownership by 48% to 18,516 units (SEC Form 4)

      4 - Lifeward Ltd. (0001607962) (Issuer)

      12/17/24 8:55:09 AM ET
      $LFWD
      Industrial Specialties
      Health Care

    $LFWD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Turk Joseph E Jr bought $10,140 worth of Ordinary Shares (6,000 units at $1.69), increasing direct ownership by 48% to 18,516 units (SEC Form 4)

      4 - Lifeward Ltd. (0001607962) (Issuer)

      12/17/24 8:55:09 AM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Director Swinford Michael bought $43,858 worth of Ordinary Shares (21,622 units at $2.03), increasing direct ownership by 50% to 65,040 units (SEC Form 4)

      4 - Lifeward Ltd. (0001607962) (Issuer)

      11/27/24 8:03:53 AM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Director Swinford Michael bought $30,899 worth of Ordinary Shares (16,907 units at $1.83), increasing direct ownership by 64% to 43,418 units (SEC Form 4)

      4 - Lifeward Ltd. (0001607962) (Issuer)

      11/26/24 7:07:36 AM ET
      $LFWD
      Industrial Specialties
      Health Care

    $LFWD
    Leadership Updates

    Live Leadership Updates

    See more
    • Lifeward Announces Appointment of Robert J. Marshall to Its Board of Directors

      MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions in physical rehabilitation and recovery, announced the Board of Directors has approved the appointment of Robert J. Marshall Jr. as a new director effective November 2, 2024. As part of his duties as a director, Mr. Marshall will serve as Chairman of the Audit Committee. Mr. Marshall has had a long and accomplished finance career in the medical device industry. Currently, Mr. Marshall serves as the Chief Financial Officer and Treasurer of Lantheus Holdings, Inc., a publicly traded radiopharmaceut

      11/7/24 4:05:14 PM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Lifeward Announces Appointment of Dr. Keith E. Tansey as Consulting Director of Clinical Research

      MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™) (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today announced that Dr. Keith E. Tansey, MD, PhD, will be joining its Medical Affairs team as a consultant in the role of Director, Clinical Research. Dr. Tansey's responsibilities will include the development and stewardship of Lifeward's clinical research program, the advancement of key opinion leader opportunities, and iden

      9/10/24 8:30:00 AM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Lifeward Announces Appointment of Joseph E. Turk as Incoming Chairman of its Board of Directors

      MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, July 02, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™) (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today announced that Jeff Dykan, current Chairman of the Lifeward Board of Directors, will retire from his role and will not stand for reelection effective at the 2024 Annual Meeting of Shareholders. Joseph Turk, who has served on Lifeward's Board since 2022, has been appointed as the incoming Chairman and will assume the role f

      7/2/24 4:30:00 PM ET
      $LFWD
      Industrial Specialties
      Health Care

    $LFWD
    SEC Filings

    See more
    • SEC Form S-3 filed by Lifeward Ltd.

      S-3 - Lifeward Ltd. (0001607962) (Filer)

      5/15/25 4:06:12 PM ET
      $LFWD
      Industrial Specialties
      Health Care
    • SEC Form 10-Q filed by Lifeward Ltd.

      10-Q - Lifeward Ltd. (0001607962) (Filer)

      5/15/25 9:00:43 AM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Lifeward Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - Lifeward Ltd. (0001607962) (Filer)

      5/15/25 8:16:49 AM ET
      $LFWD
      Industrial Specialties
      Health Care

    $LFWD
    Financials

    Live finance-specific insights

    See more
    • Lifeward Ltd. Reports First Quarter 2025 Financial Results

      U.S. pipeline of ReWalk opportunities continues to build with over 120 qualified leads in process Closure of AlterG sites and resulting consolidation of resources and reduced expenditures yields improved operating expense trend Second consecutive quarter of AlterG revenue growth over 15% reflecting continued sales momentum MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced its financial results for the three months ended March 31, 2025. Recent Highlights and A

      5/15/25 8:00:33 AM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Lifeward to Report First Quarter 2025 Financial Results on May 15, 2025

      MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a  global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its first quarter 2025 financial results before the markets open on Thursday, May 15, 2025. Larry Jasinski, Chief Executive Officer, and Mike Lawless, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EDT to discuss the financial results. To access the call, analysts and investors may utilize the following: Toll free (U.S.)1-833-316-0561International (

      5/7/25 4:30:25 PM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Lifeward to Report Fourth Quarter and Fiscal Year-End 2024 Financial Results on March 7, 2025

      MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a  global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its fourth quarter and fiscal year-end financial results before the markets open on Friday, March 7, 2025. Larry Jasinski, Chief Executive Officer, and Mike Lawless, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EST to discuss the financial results. To access the call, analysts and investors may utilize the following: Toll free (U.S.)1-833-3

      2/28/25 8:00:16 AM ET
      $LFWD
      Industrial Specialties
      Health Care